1. Home
  2. WINA vs ZYME Comparison

WINA vs ZYME Comparison

Compare WINA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

HOLD

Current Price

$418.13

Market Cap

1.6B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$24.19

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WINA
ZYME
Founded
1988
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
WINA
ZYME
Price
$418.13
$24.19
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
64.6K
647.9K
Earning Date
04-15-2026
03-02-2026
Dividend Yield
3.23%
N/A
EPS Growth
3.76
33.33
EPS
11.30
N/A
Revenue
$86,055,700.00
$105,965,000.00
Revenue This Year
$5.55
$162.82
Revenue Next Year
$6.03
N/A
P/E Ratio
$37.98
N/A
Revenue Growth
5.86
38.87
52 Week Low
$295.79
$9.03
52 Week High
$526.81
$28.49

Technical Indicators

Market Signals
Indicator
WINA
ZYME
Relative Strength Index (RSI) 42.46 52.58
Support Level $405.17 $22.28
Resistance Level $451.93 $27.54
Average True Range (ATR) 19.63 1.20
MACD -1.60 0.04
Stochastic Oscillator 20.69 32.68

Price Performance

Historical Comparison
WINA
ZYME

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: